{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:12:07Z","timestamp":1778551927358,"version":"3.51.4"},"reference-count":78,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cpcardiol.2026.103338","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:49:37Z","timestamp":1775260177000},"page":"103338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidimensional care in transthyretin cardiac amyloidosis: Integrating extracardiac organ involvement and comorbidity management"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8383-7542","authenticated-orcid":false,"given":"Roberta","family":"Magnano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Saraullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"D\u2019Alleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Di","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Genovesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiusto","family":"Vitulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Fortuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Forlani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo Di","family":"Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.cpcardiol.2026.103338_bib0001","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"16","key":"10.1016\/j.cpcardiol.2026.103338_bib0002","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC heart failure association","volume":"47","author":"Garcia-Pavia","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11886-025-02308-6","article-title":"The weight of comorbidities in the specific treatment of ATTR-related amyloid cardiomyopathy","volume":"27","author":"Cantone","year":"2025","journal-title":"Curr Cardiol Rep"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103338_bib0005","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103338_bib0006","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0007","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jchf.2025.03.017","article-title":"Current landscape of therapies for transthyretin amyloid cardiomyopathy","volume":"13","author":"Griffin","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103338_bib0008","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of Tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100148","article-title":"Improvements in efficacy measures with Tafamidis in the Tafamidis in Transthyretin cardiomyopathy clinical trial","volume":"1","author":"Hanna","year":"2022","journal-title":"JACC Adv"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103338_bib0011","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamacardio.2025.4477","article-title":"Efficacy of acoramidis in wild-type and variant transthyretin amyloid cardiomyopathy: results from ATTRibute-CM and its open-label extension","volume":"11","author":"Alexander","year":"2025","journal-title":"JAMA Cardiol [Internet]"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.cpcardiol.2026.103338_bib0014","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0016","article-title":"Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis\u2014a clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103338_bib0018","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103338_bib0019","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ehjcvp\/pvaf033","article-title":"Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies","volume":"11","author":"Laborante","year":"2025","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0020","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10741-020-09963-7","article-title":"The role of non-invasive devices for the telemonitoring of heart failure patients","volume":"26","author":"Faragli","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"31","key":"10.1016\/j.cpcardiol.2026.103338_bib0021","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/eurheartj\/ehad280","article-title":"Telemonitoring for heart failure: a meta-analysis","volume":"44","author":"Scholte","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.transproceed.2020.08.020","article-title":"Outcomes of heart transplantation in cardiac amyloidosis patients: a single center experience","volume":"53","author":"Chen","year":"2021","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103338_bib0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1253\/circrep.CR-23-0022","article-title":"Prevalence and treatment of arrhythmias in patients with transthyretin and light-chain cardiac amyloidosis","volume":"5","author":"Miyamoto","year":"2023","journal-title":"Circ Rep"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103338_bib0024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jjcc.2024.03.008","article-title":"Atrial fibrillation in the setting of cardiac amyloidosis \u2013 a review of the literature","volume":"84","author":"Bazoukis","year":"2024","journal-title":"J Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103338_bib0025","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.19102\/icrm.2021.120605","article-title":"Clinical outcomes and disease burden in amyloidosis patients with and without atrial fibrillation\u2014insight from the national inpatient sample database","volume":"12","author":"Jamal","year":"2021","journal-title":"J Innov Card Rhythm Manag"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103338_bib0026","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jcmg.2023.01.015","article-title":"Prognostic utility of left atrial strain to predict thrombotic events and mortality in amyloid cardiomyopathy","volume":"16","author":"Akintoye","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103338_bib0027","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103338_bib0028","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.recesp.2022.07.011","article-title":"Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study","volume":"76","author":"Amat-Santos","year":"2023","journal-title":"Rev Esp Cardiol Engl Ed"},{"issue":"13","key":"10.1016\/j.cpcardiol.2026.103338_bib0029","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement_1","key":"10.1016\/j.cpcardiol.2026.103338_bib0030","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehab724.1810","article-title":"Management strategies for atrial fibrillation and flutter in patients with transthyretin cardiac amyloidosis","volume":"42","author":"Dale","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103338_bib0031","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0033","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1002\/ehf2.14082","article-title":"Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants","volume":"9","author":"Touboul","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2020.01.002","article-title":"Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter","volume":"222","author":"Loungani","year":"2020","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103338_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae155","article-title":"Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia","volume":"26","author":"Kanazawa","year":"2024","journal-title":"Europace"},{"issue":"Supplement_1","key":"10.1016\/j.cpcardiol.2026.103338_bib0036","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/europace\/euaf085.152","article-title":"Safety and efficacy of catheter ablation in patients with atrial arrhythmias and cardiac amyloidosis: a systematic review and meta-analysis","volume":"27","author":"Mazetto Silva Vieira","year":"2025","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0037","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 The transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"145","key":"10.1016\/j.cpcardiol.2026.103338_bib0038","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0046-2017","article-title":"The lung in amyloidosis","volume":"26","author":"Milani","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103338_bib0039","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3390\/life13061299","article-title":"Cardiovascular diseases in COPD: from diagnosis and prevalence to therapy","volume":"13","author":"Papaporfyriou","year":"2023","journal-title":"Life"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103338_bib0040","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/jcm12113684","article-title":"Risk stratification in transthyretin cardiac amyloidosis: the added value of lung spirometry","volume":"12","author":"Banydeen","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0041","unstructured":"GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2025 Report [Internet]. Available from: https:\/\/goldcopd.org\/2025-gold-report\/#:~:text=The%202025%20GOLD%20Report%20is%20an%20evidence%2Dbased,Background%20information%20about%20COPD%20*%20Management%20recommendations."},{"issue":"10030","key":"10.1016\/j.cpcardiol.2026.103338_bib0042","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0043","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2024.07.020","article-title":"Impact of anemia on mortality and morbidity in transthyretin amyloid cardiomyopathy","volume":"228","author":"Wardhere","year":"2024","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103338_bib0044","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ehf2.13818","article-title":"Prevalence and determinants of iron deficiency in cardiac amyloidosis","volume":"9","author":"Jobb\u00e9-Duval","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2023.100063","article-title":"The impact of iron deficiency on disease severity and myocardial function in cardiac amyloidosis","volume":"11","author":"Martens","year":"2024","journal-title":"Am J Med Open"},{"issue":"10266","key":"10.1016\/j.cpcardiol.2026.103338_bib0046","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"The Lancet"},{"issue":"48","key":"10.1016\/j.cpcardiol.2026.103338_bib0047","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"issue":"37","key":"10.1016\/j.cpcardiol.2026.103338_bib0048","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"Von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133027","article-title":"Prognostic impact of hypertension and diabetes in patients with cardiac amyloidosis","volume":"424","author":"Argir\u00f2","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133567","article-title":"The complementary effects of GLP-1 receptor agonists and SGLT2 inhibitors in transthyretin cardiac amyloidosis patients: a retrospective multicenter cohort study","volume":"438","author":"Mahmoud","year":"2025","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0051","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103338_bib0052","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103338_bib0053","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jaccao.2024.03.004","article-title":"Learning from trials","volume":"6","author":"Obici","year":"2024","journal-title":"JACC Cardio Oncology"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103338_bib0054","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2024.01.527","article-title":"Hereditary transthyretin amyloidosis and the impact of classic and new treatments on kidney function: a review","volume":"84","author":"Mel\u00e9ndrez-Balc\u00e1zar","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103338_bib0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of Tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC Cardio Oncology"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103338_bib0056","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/genes13122236","article-title":"Trajectories of kidney function in patients with ATTRv treated with gene silencers","volume":"13","author":"Luigetti","year":"2022","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0057","first-page":"57","article-title":"Neuropathic involvement in wild-type transthyretin amyloidosis","volume":"11","author":"Morato-Mart\u00edn","year":"2025","journal-title":"Neurolog\u00eda"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0058","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-21745-5","article-title":"Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags","volume":"15","author":"Siemer","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1345608","article-title":"Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center\u2019s experience","volume":"11","author":"\u017divkovi\u0107","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103338_bib0060","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0061","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0062","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103338_bib0063","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0064","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/pin.13041","article-title":"Distribution of amyloidosis subtypes based on tissue biopsy site \u2212 consecutive analysis of 729 patients at a single amyloidosis center in Japan","volume":"71","author":"Abe","year":"2021","journal-title":"Pathol Int"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103338_bib0066","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.dld.2023.11.025","article-title":"Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: recommendations from an Italian group of experts","volume":"56","author":"Cappello","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103338_bib0067","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1111\/jgh.70083","article-title":"Amyloidosis for the gastroenterologist: a comprehensive systematic review of diagnosis and management of gastrointestinal manifestations","volume":"40","author":"Tang","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103338_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101784","article-title":"Cardiac amyloidosis in older adults with a focus on frailty","volume":"4","author":"Bart","year":"2025","journal-title":"JACC Adv"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0069","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","article-title":"Impact of Vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"12","author":"Obici","year":"2023","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103338_bib0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103338_bib0071","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-094614","article-title":"Anxiety and depression in cardiac amyloidosis: a systematic review","volume":"15","author":"Ghinassi","year":"2025","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103338_bib0072","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jacc.2021.11.029","article-title":"Interventions for frailty among older adults with cardiovascular disease","volume":"79","author":"Ijaz","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0073","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12955-017-0759-9","article-title":"Is the Hospital anxiety and depression scale (HADS) a valid measure in a general population 65\u201380 years old? A psychometric evaluation study","volume":"15","author":"Djukanovic","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cpcardiol.2026.103338_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.1066224","article-title":"Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis","volume":"13","author":"Smorti","year":"2023","journal-title":"Front Psychol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103338_bib0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-12-84","article-title":"A confirmatory bifactor analysis of the hospital anxiety and depression scale in an Italian community sample","volume":"12","author":"Iani","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103338_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101123","article-title":"Comprehensive geriatric assessment to optimize the management of older patients with transthyretin cardiac amyloidosis","volume":"3","author":"Fumagalli","year":"2024","journal-title":"JACC Adv"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103338_bib0077","article-title":"Prognostic value of malnutrition, frailty, and physical performance in transthyretin cardiac amyloidosis: insights from a prospective multicenter cohort study","volume":"18","author":"Fumagalli","year":"2025","journal-title":"Circ Heart Fail [Internet]"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103338_bib0078","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jaccao.2025.01.018","article-title":"Clinical phenotype and prognostic significance of frailty in transthyretin cardiac amyloidosis","volume":"7","author":"Fumagalli","year":"2025","journal-title":"JACC CardioOncology"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:30:22Z","timestamp":1778549422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0146280626000800"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103338","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidimensional care in transthyretin cardiac amyloidosis: Integrating extracardiac organ involvement and comorbidity management","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103338"}}